Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Merck is strong in cash and balance sheet and will have continued growth in their highest-margin product while being greatly undervalued. See why MRK stock is a Buy.

SAN FRANCISCO -- Patients with colon cancer and comorbid obesity treated with GLP-1 receptor agonists had lower mortality and ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

During Fast Company and Johns Hopkins University’s World Changing Ideas Summit last November, we asked leaders what are the ...

Gallbladder cancer is a rare and often aggressive malignancy that develops in the tissues of the gallbladder — a small, ...

Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...

Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people ...

If a recession were to hit, it’s a foregone conclusion that people won’t stop taking their prescriptions, and they won’t ...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such ...